Curated News
By: NewsRamp Editorial Staff
August 18, 2026
Regentis Biomaterials Strengthens GelrinC Manufacturing and IP with New Patents
TLDR
- Regentis secures Japanese patent for GelrinC, expanding IP to nearly 30 patents, and boosts yield fivefold, positioning ahead in cartilage repair.
- Regentis's organic solvent-free manufacturing process increases yield fivefold, simplifies production, and supports commercial scale for GelrinC.
- Regentis's off-the-shelf GelrinC offers a simpler, cost-effective alternative to cell-based procedures, potentially improving access to knee cartilage repair for many.
- GelrinC is a cell-free hydrogel that resorbs in the knee, prompting surrounding cells to regenerate cartilage—a novel approach to tissue repair.
Impact - Why it Matters
This news matters because Regentis Biomaterials is overcoming key barriers to commercialization of its off-the-shelf cartilage repair product, GelrinC. The enhanced manufacturing process and expanded patent portfolio not only reduce production costs and complexity but also protect the technology in key markets, including Japan and the U.S. For patients suffering from knee cartilage damage, GelrinC could offer a more accessible and less invasive treatment option than existing cell-based therapies. For investors, these milestones signal the company's progress toward regulatory approval and market entry, potentially positioning Regentis as a leader in the regenerative medicine space.
Summary
Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC cartilage-repair technology with significant manufacturing and intellectual property milestones. The company recently received a Japanese Notice of Allowance for patent protection covering its organic solvent-free manufacturing process and ready-to-use liquid formulation, following a U.S. issuance that expanded its global IP portfolio to nearly 30 patents. This proprietary process increases yield fivefold, simplifies production, and is designed for commercial-scale manufacturing, positioning GelrinC as an off-the-shelf alternative to complex and costly cell-based procedures.
As Regentis progresses toward broader commercialization, it has begun European commercialization efforts following CE Mark approval and is advancing its pivotal U.S. trial beyond 50% enrollment, with premarket approval preparation targeted for the end of 2027. GelrinC addresses a market of approximately 470,000 cases for cartilage knee repair annually in the U.S., where no off-the-shelf treatment currently exists. To view the full article, visit https://ibn.fm/ILwoP.
Regentis Biomaterials is a regenerative medicine company focused on developing innovative tissue repair solutions, with its Gelrin platform technology based on synchronized, degradable hydrogel implants. The company's lead product, GelrinC(R), is a cell-free hydrogel that regenerates damaged cartilage in the knee. This content has been disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid investor awareness and marketing engagement, and the latest news and updates are available in the company's newsroom at https//ibn.fm/RGNT.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Regentis Biomaterials Strengthens GelrinC Manufacturing and IP with New Patents
